JP2020531523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531523A5 JP2020531523A5 JP2020511307A JP2020511307A JP2020531523A5 JP 2020531523 A5 JP2020531523 A5 JP 2020531523A5 JP 2020511307 A JP2020511307 A JP 2020511307A JP 2020511307 A JP2020511307 A JP 2020511307A JP 2020531523 A5 JP2020531523 A5 JP 2020531523A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- period
- weeks
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 238000012423 maintenance Methods 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 229960003121 arginine Drugs 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000009697 arginine Nutrition 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 claims 1
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 102000054960 human MASP2 Human genes 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550328P | 2017-08-25 | 2017-08-25 | |
| US62/550,328 | 2017-08-25 | ||
| PCT/US2018/047255 WO2019040453A1 (en) | 2017-08-25 | 2018-08-21 | HIGHLY CONCENTRATED MASP-2 INHIBITOR ANTIBODY FORMULATIONS WITH LOW VISCOSITY, KITS AND METHODS FOR TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531523A JP2020531523A (ja) | 2020-11-05 |
| JP2020531523A5 true JP2020531523A5 (enExample) | 2021-09-30 |
Family
ID=65436837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511307A Pending JP2020531523A (ja) | 2017-08-25 | 2018-08-21 | 高度に濃縮された低粘度のｍａｓｐ−２阻害抗体製剤、キット、および非定型溶血性症候群に罹患した対象の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190062455A1 (enExample) |
| EP (1) | EP3672994A4 (enExample) |
| JP (1) | JP2020531523A (enExample) |
| KR (1) | KR20200037863A (enExample) |
| CN (1) | CN111278863A (enExample) |
| AU (1) | AU2018322032B2 (enExample) |
| BR (1) | BR112020003632A2 (enExample) |
| CA (1) | CA3072913A1 (enExample) |
| CL (1) | CL2020000397A1 (enExample) |
| IL (1) | IL272673B2 (enExample) |
| MA (1) | MA49960A (enExample) |
| MX (1) | MX2020002077A (enExample) |
| RU (1) | RU2020111574A (enExample) |
| TW (1) | TW201925224A (enExample) |
| WO (1) | WO2019040453A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4057980A1 (en) * | 2019-11-15 | 2022-09-21 | F. Hoffmann-La Roche AG | Prevention of visible particle formation in aqueous protein solutions |
| TW202135860A (zh) * | 2019-12-10 | 2021-10-01 | 美商再生元醫藥公司 | 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| WO2022026914A1 (en) * | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| US20230416406A1 (en) * | 2022-03-10 | 2023-12-28 | Omeros Corporation | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101875155B1 (ko) * | 2011-05-02 | 2018-07-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| EP2704743B1 (en) * | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| CN118924900A (zh) * | 2012-06-18 | 2024-11-12 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
| WO2015058143A1 (en) * | 2013-10-17 | 2015-04-23 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| WO2016094834A2 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
| SG10202011469UA (en) * | 2015-11-09 | 2020-12-30 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2018
- 2018-08-21 US US16/106,986 patent/US20190062455A1/en not_active Abandoned
- 2018-08-21 IL IL272673A patent/IL272673B2/en unknown
- 2018-08-21 EP EP18847767.3A patent/EP3672994A4/en not_active Withdrawn
- 2018-08-21 BR BR112020003632-3A patent/BR112020003632A2/pt unknown
- 2018-08-21 JP JP2020511307A patent/JP2020531523A/ja active Pending
- 2018-08-21 WO PCT/US2018/047255 patent/WO2019040453A1/en not_active Ceased
- 2018-08-21 CN CN201880054825.8A patent/CN111278863A/zh active Pending
- 2018-08-21 CA CA3072913A patent/CA3072913A1/en active Pending
- 2018-08-21 AU AU2018322032A patent/AU2018322032B2/en active Active
- 2018-08-21 MX MX2020002077A patent/MX2020002077A/es unknown
- 2018-08-21 KR KR1020207008257A patent/KR20200037863A/ko not_active Ceased
- 2018-08-21 RU RU2020111574A patent/RU2020111574A/ru unknown
- 2018-08-21 MA MA049960A patent/MA49960A/fr unknown
- 2018-08-22 TW TW107129307A patent/TW201925224A/zh unknown
-
2020
- 2020-02-18 CL CL2020000397A patent/CL2020000397A1/es unknown
-
2023
- 2023-10-04 US US18/480,825 patent/US20240247078A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12485173B2 (en) | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | |
| JP4879884B2 (ja) | 抗−ｉｌ−９抗体製剤及びその使用法 | |
| ES2788515T3 (es) | Formulaciones liofilizadas y acuosas de anticuerpos anti-CD40 | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| RU2013125775A (ru) | Способы лечения ревматоидного артрита с применением антагонистов il-17 | |
| JP7551822B2 (ja) | 治療用抗体製剤 | |
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| JP2020531523A5 (enExample) | ||
| US20200369760A1 (en) | Stabilized formulations containing anti-angptl3 antibodies | |
| KR20150032941A (ko) | 약학 제제 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| US20210393777A1 (en) | Stable preparation comprising anti-pcsk9 antibody | |
| JPWO2020243031A5 (enExample) | ||
| JPWO2021243298A5 (enExample) | ||
| JP2020531521A5 (enExample) | ||
| RU2025100421A (ru) | Состав на основе антитела к компоненту c1s системы комплемента | |
| RU2024133531A (ru) | Стабильные высококонцентрированные составы на основе аргинина, содержащие антитело к pd-1, и способы их применения | |
| EA045866B1 (ru) | Состав терапевтического антитела | |
| HK40050174A (en) | Stable formulation containing anti-pcsk9 antibody | |
| NZ737043A (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| NZ737043B2 (en) | Treatment of beta-thalassemia using actrii ligand traps |